# Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2)

> **NCT04797650** · PHASE3 · COMPLETED · sponsor: **Concert Pharmaceuticals** · enrollment: 517 (actual)

## Conditions studied

- Alopecia Areata

## Interventions

- **DRUG:** CTP-543 matching placebo
- **DRUG:** CTP-543

## Key facts

- **NCT ID:** NCT04797650
- **Lead sponsor:** Concert Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-10
- **Primary completion:** 2022-06-08
- **Final completion:** 2022-06-29
- **Target enrollment:** 517 (ACTUAL)
- **Last updated:** 2023-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04797650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04797650, "Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2)". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT04797650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*